Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTA: LY3056480 in stable SNHL
NCT05061758Phase 2Withdrawn
- Sponsor
- Audion Therapeutics
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY3056480 in sensorineural hearing loss (SNHL), sponsored by Audion Therapeutics. Planned start Sep 2022; status: withdrawn.
02
Drugs
LY3056480
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT05061758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061758.